STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
Stat News • 6/5/2026 – 6/8/2026
Summary
No summary yet.
Advertisement
Cluster Activity
1
1
1
2026-06-052026-06-07
Lindy Score Breakdown (V4.2)
11h
Age
1
Sources
from cluster
2
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier97% (0.5^2/48)
Hero EligibleYes
Story Timeline
- 2026-06-05
- 2026-06-06
- 2026-06-07STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA (current)
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Same Story from 3 sources
Breaking Similar stories
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Stat News • Today
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
Stat News • 1 day ago
STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
Stat News • 1 day ago
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
Stat News • 1 day ago
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
Stat News • 2 days ago
STAT+: What stripping civil service protections for thousands of federal workers will mean for HHS
Stat News • 2 days ago
STAT+: Up and down the ladder: The latest comings and goings
Stat News • 2 days ago
STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
Stat News • 2 days ago
STAT+: Will Makary’s FDA voucher program survive?
Stat News • 2 days ago
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
Stat News • 2 days ago